Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.

<h4>Background</h4>Imatinib mesylate (IM) is a first-line treatment option for patients with chronic myeloid leukemia (CML). Patients who fail or are intolerant to IM therapy are treated with more expensive second and third-generation tyrosine kinase inhibitors. Patients show wide variat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kibum Kim, Gwendolyn A McMillin, Philip S Bernard, Srinivas Tantravahi, Brandon S Walker, Robert L Schmidt
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0226552&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items